|
Esophageal Neoplasms
|
0.600 |
CausalMutation
|
group |
CGI |
|
|
|
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
EGFR mutations in esophageal carcinoma are rare but do exist, and thus gefitinib could be included in esophageal cancer treatment regimens by selecting those patients who possess such mutations.
|
17142003 |
2007 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
EGFR mutations in esophageal carcinoma are rare but do exist, and thus gefitinib could be included in esophageal cancer treatment regimens by selecting those patients who possess such mutations.
|
17142003 |
2007 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Epidermal growth factor receptor (EGFR), found in the epithelium of the digestive tract, plays an important role in epithelial repair and shows increased expression in different neoplasms, including esophageal tumors.
|
22875307 |
2013 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.
|
23377570 |
2014 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer.
|
28498434 |
2017 |
|
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Both YAP1 and EGFR are overexpressed in resistant esophageal cancer tissues compared with sensitive esophageal cancer tissues.
|
25739674 |
2015 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Expression and prognostic influence of NF-κB and EGFR in esophageal cancer.
|
26681028 |
2015 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Gene-gene interaction of EGFR 497Arg>Lys and EGF +61A>G polymorphisms enhanced risk for EC, indicating additive effects.
|
18773861 |
2008 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Gene-gene interaction of EGFR 497Arg>Lys and EGF +61A>G polymorphisms enhanced risk for EC, indicating additive effects.
|
18773861 |
2008 |
|
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In this report, the effect of PYM on EGFR expression in human esophageal cancer cells and the therapeutic efficacy of the combination of PYM and cetuximab on esophageal cancer xenograft were investigated.
|
22311160 |
2012 |
|
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In this study, we first evaluated EGFR gene and protein expression in 70 Chinese EC patient tumor samples collected during surgery.
|
28881608 |
2017 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer.
|
17912028 |
2007 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
|
21207425 |
2011 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
|
22042947 |
2011 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
More than 50% EGFR-positive EsC and MPM cells were resistant to EGFR-TKI, and susceptibility to EGFR-TKI growth-inhibitory effect correlated positively with expression of E-cadherin (epithelial gene marker) and negatively with mesenchymal gene markers.
|
23749888 |
2013 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR), the efficacy of nimotuzumab added to nCRT for esophageal cancer is uncertain.
|
31258850 |
2019 |
|
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Northern blot analysis revealed a fourfold increase (p < 0.01) in EGF-R mRNA levels in the esophageal cancer samples in comparison with normal tissue samples.
|
10512940 |
1999 |
|
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Over-expression of epidermal growth factor receptor in esophageal cancer is associated with poor prognosis.
|
22555809 |
2012 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Presently, the single nucleotide polymorphisms (SNPs) of EGFR/PLCE1 genes and their associations with EC survival remain unclear.
|
31209807 |
2019 |
|
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Real-time quantitative polymerase chain reaction technology (RT-PCR) was used to detect the expression of VEGF, HER-2, and EGFR mRNA in esophageal squamous cancer tissue of 60 cases and 30 cases of VEGF, HER-2, and EGFR mRNA in esophageal cancer adjacent tissues, and analyze its relationship with clinicopathological features.
|
26099724 |
2015 |
|
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Results indicated that PT shows more effective antitumor activity as compared with Pan both on EGFR-overexpressed KYSE-450 and KYSE-150 esophageal cancer cells, especially on KYSE-450 cells.
|
30596104 |
2018 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Results of this study suggest that anti-EGFR therapies should be investigated in prospective clinical trials in different settings in EGFR FISH-positive and, in particular, EGFR-amplified esophageal cancer.
|
28537764 |
2017 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Targeting the human EGFR family in esophagogastric cancer.
|
21468131 |
2011 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The EGFR CA repeat genetic polymorphism may act as a valuable molecular predictor of clinical outcome of esophageal cancer after CCRT and esophagectomy, especially in those with good response to CCRT.
|
21298351 |
2011 |